Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis.
Osteoporos Int. 2013 Aug; 24(8):2291-300.OI

Abstract

The results of this study suggest that, under the assumption of same relative risk reduction of fractures in men as for women, strontium ranelate could be considered a cost-effective strategy compared with no treatment for the treatment of osteoporotic men from a Belgian healthcare payer perspective.

INTRODUCTION

This study was conducted to estimate the cost-effectiveness of strontium ranelate in the treatment of osteoporotic men.

METHODS

A previously validated Markov microsimulation model was adapted to estimate the cost (<euro>2,010) per quality-adjusted life-year (QALY) gained of strontium ranelate compared with no treatment. Similar efficacy data on lumbar spine and femoral neck bone mineral density (BMD) between men with osteoporosis at high risk of fracture (MALEO Trial) and postmenopausal osteoporotic women (pivotal SOTI, TROPOS trials) supports the assumption, in the base-case analysis, of the same relative risk reduction of fractures in men as for women. Analyses were conducted, from a Belgian healthcare payer perspective, in the population from the MALEO Trial who is a men population with a mean age of 73 years, and BMD T-score ≤-2.5 or prevalent vertebral fracture (PVF).

RESULTS

In the MALEO population, strontium ranelate compared with no treatment was estimated at <euro>49,798 and <euro>25,584 per QALY gained using efficacy data from the intent-to-treat analysis and the per-protocol analysis including only adherent patients, respectively. In men with a BMD T-score ≤-2.5 or with PVF, the cost per QALY gained of strontium ranelate fall below thresholds of <euro>45,000 and <euro>25,000 per QALY gained based on efficacy data from the entire population of the clinical trial and from the per-protocol analyses, respectively.

CONCLUSIONS

The results of this study suggest that, under the assumption of same relative risk reduction of fractures in men as for women, strontium ranelate could be considered cost-effective compared with no treatment for male osteoporosis.

Links

PMC Free PDF
PMC Free Full Text

Authors+Show Affiliations

Hiligsmann M
Department of Health Services Research, School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, The Netherlands. m.hiligsmann@maastrichtuniversity.nl
Ben Sedrine W
No affiliation info available
Bruyère O
No affiliation info available
Reginster JY
No affiliation info available

MeSH

AgedBelgiumBone DensityBone Density Conservation AgentsCost-Benefit AnalysisDrug CostsFemaleFemur NeckHealth Care CostsHumansIncidenceLumbar VertebraeMaleModels, EconometricOsteoporosisOsteoporotic FracturesQuality-Adjusted Life YearsThiophenes

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23371359

Citation

Hiligsmann, M, et al. "Cost-effectiveness of Strontium Ranelate in the Treatment of Male Osteoporosis." Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 24, no. 8, 2013, pp. 2291-300.
Hiligsmann M, Ben Sedrine W, Bruyère O, et al. Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporos Int. 2013;24(8):2291-300.
Hiligsmann, M., Ben Sedrine, W., Bruyère, O., & Reginster, J. Y. (2013). Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 24(8), 2291-300. https://doi.org/10.1007/s00198-013-2272-2
Hiligsmann M, et al. Cost-effectiveness of Strontium Ranelate in the Treatment of Male Osteoporosis. Osteoporos Int. 2013;24(8):2291-300. PubMed PMID: 23371359.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. AU - Hiligsmann,M, AU - Ben Sedrine,W, AU - Bruyère,O, AU - Reginster,J-Y, Y1 - 2013/02/01/ PY - 2012/09/14/received PY - 2013/01/08/accepted PY - 2013/2/2/entrez PY - 2013/2/2/pubmed PY - 2014/4/20/medline SP - 2291 EP - 300 JF - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA JO - Osteoporos Int VL - 24 IS - 8 N2 - UNLABELLED: The results of this study suggest that, under the assumption of same relative risk reduction of fractures in men as for women, strontium ranelate could be considered a cost-effective strategy compared with no treatment for the treatment of osteoporotic men from a Belgian healthcare payer perspective. INTRODUCTION: This study was conducted to estimate the cost-effectiveness of strontium ranelate in the treatment of osteoporotic men. METHODS: A previously validated Markov microsimulation model was adapted to estimate the cost (<euro>2,010) per quality-adjusted life-year (QALY) gained of strontium ranelate compared with no treatment. Similar efficacy data on lumbar spine and femoral neck bone mineral density (BMD) between men with osteoporosis at high risk of fracture (MALEO Trial) and postmenopausal osteoporotic women (pivotal SOTI, TROPOS trials) supports the assumption, in the base-case analysis, of the same relative risk reduction of fractures in men as for women. Analyses were conducted, from a Belgian healthcare payer perspective, in the population from the MALEO Trial who is a men population with a mean age of 73 years, and BMD T-score ≤-2.5 or prevalent vertebral fracture (PVF). RESULTS: In the MALEO population, strontium ranelate compared with no treatment was estimated at <euro>49,798 and <euro>25,584 per QALY gained using efficacy data from the intent-to-treat analysis and the per-protocol analysis including only adherent patients, respectively. In men with a BMD T-score ≤-2.5 or with PVF, the cost per QALY gained of strontium ranelate fall below thresholds of <euro>45,000 and <euro>25,000 per QALY gained based on efficacy data from the entire population of the clinical trial and from the per-protocol analyses, respectively. CONCLUSIONS: The results of this study suggest that, under the assumption of same relative risk reduction of fractures in men as for women, strontium ranelate could be considered cost-effective compared with no treatment for male osteoporosis. SN - 1433-2965 UR - https://www.unboundmedicine.com/medline/citation/23371359/Cost_effectiveness_of_strontium_ranelate_in_the_treatment_of_male_osteoporosis_ L2 - https://doi.org/10.1007/s00198-013-2272-2 DB - PRIME DP - Unbound Medicine ER -